top of page


Molecular RT-PCR is widely accepted in clinical practice and is commonly used as the gold standard for respiratory pathogen testing. Its reliability and accuracy contribute to its widespread adoption by clinicians. Molecular RPP testing is often preferred for a detailed analysis of respiratory pathogens.



High Sensitivity and Specificity:

This highly sensitive and specific test allows for the detection of even low amounts of viral RNA. This is crucial for accurate identification of respiratory pathogens, especially in the early stages of infection.

Quantitative Analysis:

Molecular RPP testing provides quantitative information about the viral load, allowing for the estimation of the amount of viral genetic material present in a sample. This can be valuable for monitoring disease progression and assessing treatment effectiveness.

Rapid Turnaround Time:

Test results are quick, especially when compared to traditional culture-based methods. Rapid diagnosis is essential for implementing timely treatment and containment measures.

Multiplexing Capability:

Molecular RPP detects multiple pathogens simultaneously in a single assay. This multiplexing capability is advantageous for screening and identifying a broad range of respiratory viruses in

a single test, saving time and resources.

Detection of RNA Viruses:

Molecular RPP testing detects RNA viruses, which include many respiratory pathogens such as influenza, SARS-CoV-2, and respiratory syncytial virus (RSV).

Early Detection:

Molecular RPP can detect viral RNA even before the onset of symptoms, allowing for early identification of infections. Early detection is crucial for implementing appropriate public health measures and preventing the spread of respiratory pathogens.

Broad Spectrum of Pathogens:

Molecular RPP assays are designed to detect a wide variety of respiratory pathogens, including viruses and bacteria. This versatility makes this test a valuable tool for comprehensive respiratory pathogen testing.

Adaptability to Emerging Strains:

Molecular RPP can detect new or emerging strains of respiratory pathogens. This adaptability is essential for staying ahead of evolving infectious diseases.

35 Pathogens Tested

Bordetella bronchiseptica 

parapertussis / pertussis

Bordetella pertussis

Chlamydophila pneumoniae

Haemophilus influenzae

Klebsiella pneumoniae

Legionella pneumophila

Mycoplasma pneumoniae

Human Enterovirus D68

Human Metapneumovirus (hMPV)

Human Parainfluenza virus 1

Human Parainfluenza virus 2

Human Parainfluenza virus 3

Human Parainfluenza virus 4

Human Respiratory Syncytial Virus A (RSVA)

Staphylococcus aureus Streptococcus pneumoniae Adenovirus

Human Coronavirus 229E

Human Coronavirus HKU1

Human Coronavirus NL63

Human Coronavirus OC43

Human Enterovirus (pan assay)

Human Respiratory Syncytial Virus B (RSVB)

Human Rhinovirus 1/2

Human Rhinovirus 2/2

Human herpesvirus 4

(HHV4 – Epstein-Barr Virus)

Human herpesvirus 5

(HHV5 – Cytomegalovirus)

Human herpesvirus 6 (HHV6)

Influenza A

Influenza A/H1-2009

Influenza A/H3

Influenza B

SARS-CoV-2 S Protein

SARS-CoV-2 N Protein

AdobeStock_72648835 Doc with pills.jpeg

Phi Life Sciences Molecular RPP Testing Includes:


• NP Swab with with transfer tube and biohazard bag.

• Comprehensive collection instructions.

• Return shipping or sample pick up.

• On line result reporting 24-48 hours after sample receipt.

• Easy to interpret patient-focused report which allows providers

to effectively address pathogens while maintaining responsible antibiotic stewardship.

bottom of page